SPRY: ARS Pharmaceuticals Inc Company Profile & Statistics

About

ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites. ARS Pharmaceuticals Inc., formerly known as Silverback Therapeutics Inc., is based in SEATTLE.

Info & Links

CEO

Richard Lowenthal

Headquarters

11682 El Camino Real, Suite 120
San Diego, CA 92130, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

ARS Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization²

1.14B

Enterprise Value

1.10B

Enterprise Value/EBITDA(ttm)

-16.22

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

Price to Book(mrq)

5.74

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

48.65%

Operating Margin(ttm)

Profit Margin(ttm)

-857.04%

Return on Equity(ttm)

-22.56%

Return on Invested Capital(ttm)

-23.04%

Return on Assets(ttm)

-21.82%

Income Statement

Revenue(ttm)

2.57M

Revenue Per Share(ttm)

0.03

Gross Profit(ttm)

2.46M

EBITDA(ttm)³

-67.91M

Net Income Available to Common(ttm)

-49.10M

Diluted EPS(ttm)

-0.51

Share Statistics

Beta (5Y Monthly)

0.88

52-Week Change

125.43%

S&P 500 52-Week Change

27.63%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

97.19M

Dividend Yield

0.00%

Float⁴

58.21M

% Held by Insiders

40.10%

% Held by Institutions

68.16%

Balance Sheet

Total Cash(mrq)

204.62M

Total Cash Per Share(mrq)

2.11

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

12.56%

Quick Ratio(mrq)

12.52%

Book Value Per Share(mrq)

2.07

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.29

Free Cash Flow(ytd)

-28.72M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

SPRY

ARS Pharmaceuticals Inc

ARS Pharmaceuticals Inc Profile